3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer

Ottawa Hospital Research Institute72 enrolled

Overview

In this study we are comparing two forms of radiotherapy. This study is being done because it is not clear at present time whether intensity modulated radiotherapy (IMRT) can reduce side effects of radiotherapy compared to standard radiotherapy (called 3D-Conformal Radiotherapy).

Radical radiation therapy plays an important role in the management of prostate cancer, yielding comparable long-term outcomes to surgery. Unfortunately, long term disease free survival data using PSA criteria have shown that less than 50% of high-risk patients are free of disease at 10 years. To improve on the results of conventional dose radiotherapy dose escalation with three-dimensional conformal radiation has been employed. Due to the irregular shape of the prostate and the variable motion of this organ there is substantial radiation of adjacent normal surrounding tissue during treatment which results in radiation-induced toxicity. Intensity-modulated radiation therapy (IMRT) is a new form of radiation therapy. Preliminary evidence suggests that IMRT improves the dose distribution during radiation therapy of the prostate. The hypothesis of this study is that IMRT delivered using Helical Tomotherapy can reduce late toxicity of radical radiotherapy as compared to three-dimensional conformal radiation (3DCRT) in high-risk prostate cancer patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

Arm B: Helical Tomotherapy Intensity Modulated RadiotherapyRADIATION

IMRT using Helical Tomotherapy\* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks * Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23 * Boost IMRT to Prostate 3,200 cGy/16

Arm A: 3D-Conformal RadiationOTHER

3DCRT 7800 cGY/39 Fractions/ STD Technique\* once daily Monday to Friday for 8 weeks * Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23 * Boost 6 F 3DCRT to Prostate 3,200 cGy/16

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. A pathologic diagnosis of adenocarcinoma of the prostate 2. Age greater than 18 years 3. ECOG performance status of 2 or less. 4. Presence of any of the following high risk features: * Clinical stage cT3-4 or * Gleason score 8-10 or * Pre-treatment PSA \> 20ng/ml or * Clinical N1/N2 or pathologic N1/N2 Exclusion Criteria: 1. Patients with contraindication to radical radiation therapy including inflammatory bowel disease 2. Prior or active malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer 3. Prior pelvic radiotherapy for other malignancies 4. Prior cytotoxic chemotherapy 5. Prior orchiectomy, radical prostatectomy, cryotherapy or thermal ablation therapy for prostate cancer

Locations (1)

The Ottawa Hospital Regional Cancer Centre

Ottawa, Ontario, Canada

Outcomes

Primary Outcomes

Late rectal toxicity from radiotherapy of the prostate

Outcome measurements will be determined by physical exam and bloodwork.

Time frame: Month 1, 4, 8, every 4 months during year 1-2, then every 6 months during years 2-5, then every 12 months until disease progression

Secondary Outcomes

Acute rectal toxicity, Acute and late bladder toxicity, Disease specific survival at 5 years, Biochemical relapse free survival at 5 years, Local control rates at 5 years, Quality of Life

Outcome measurements will be determined by physical exam and bloodwork.

Time frame: Month 1, 4, 8, every 4 months during year 1-2, then every 6 months during years 2-5, then every 12 months until disease progression

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.